In snakebite‑induced coagulopathy with low fibrinogen, when and how should cryoprecipitate be administered?

Cryoprecipitate in Snakebite Coagulopathy with Low Fibrinogen

Cryoprecipitate should be administered when fibrinogen falls below 1.0 g/L (100 mg/dL) in the presence of active bleeding from snakebite-induced coagulopathy, with an initial dose of 15–20 units (approximately 3–4 g fibrinogen) guided by laboratory fibrinogen levels and viscoelastic monitoring. 1, 2

When to Administer Cryoprecipitate

Fibrinogen Thresholds

• Administer cryoprecipitate when fibrinogen is < 0.8–1.0 g/L (80–100 mg/dL) in the presence of excessive microvascular bleeding. 1, 3, 2
• Transfusion is rarely indicated if fibrinogen is > 1.5 g/L (150 mg/dL) in non-pregnant patients. 1, 3, 2
• In massively bleeding patients, give cryoprecipitate empirically if fibrinogen cannot be measured promptly. 1, 2

Clinical Context for Snakebite

• Snakebite-induced venom-induced consumption coagulopathy (VICC) characteristically causes persistent hypofibrinogenemia that may require prolonged fibrinogen replacement. 4
• Coagulopathy risk should be assessed for at least 4–5 days following snakebite, as INR abnormalities can persist this long. 5
• Initial lower cholesterol levels at presentation are associated with development of overt DIC in snakebite patients. 5

How to Administer Cryoprecipitate

Initial Dosing

• Give an initial dose of 15–20 units (approximately 3–4 g fibrinogen) or 2 pooled units in a 70 kg adult. 2, 6
• Each pooled unit contains 5 individual units and provides approximately 2 g of fibrinogen. 2
• Two units per 10 kg body weight raise plasma fibrinogen concentration by roughly 1 g/L. 7, 2

Administration Technique

• Use a standard blood-giving set equipped with a 170–200 µm filter. 8, 2
• Infuse at 10–20 mL/kg/h (approximately 30–60 minutes for one pooled unit). 2
• After thawing, keep cryoprecipitate at ambient temperature for up to 4 hours; do not re-refrigerate. 8, 2
• Ensure ABO-compatible pooling before transfusion. 8, 2

Monitoring and Repeat Dosing

• Subsequent doses should be guided by viscoelastic monitoring (ROTEM/TEG) together with laboratory fibrinogen measurements. 6, 2
• Target fibrinogen levels > 1.5 g/L during active hemorrhage. 2
• Laboratory Clauss fibrinogen assays can overestimate fibrinogen when hydroxyethyl starch is present; point-of-care viscoelastic testing is preferred during active hemorrhage. 2

Important Caveats for Snakebite Coagulopathy

Evidence Against Empiric Use

• Higher antivenom doses (≥18,000 units) and transfusion of FFP or cryoprecipitate did not affect prolonged INR duration or hospital stay in overt DIC patients without bleeding. 5
• The CRYOSTAT-2 trial showed that early empiric administration of cryoprecipitate (6 g fibrinogen) did not reduce 28-day mortality compared with standard care (25.3% vs 26.1%; OR 0.96,95% CI 0.75–1.23). 9, 2
• Empiric cryoprecipitate in severely injured trauma patients did not improve survival or reduce transfusion requirements; it should be given "on-demand" guided by laboratory values. 10

Snakebite-Specific Considerations

• Snakebite coagulopathy differs from DIC caused by other diseases and is characterized by persistent fibrinogen deficiency without necessarily abnormal coagulation factor activity. 4
• Patients may manifest persistent afibrinogenemia requiring continuous large doses of human fibrinogen or cryoprecipitate over multiple days. 4
• Time to antivenom administration impacts duration of coagulopathy: patients receiving antivenom ≤6 hours had shorter time to normal fibrinogen (23:27 h vs. 31:23 h) compared to those receiving antivenom >6 hours. 11

Pre-Administration Requirements

• Verify fibrinogen ≥ 50 mg/dL (preferably ≥ 100 mg/dL) before transfusion. 2
• Ensure platelet count ≥ 50 × 10⁹/L (preferably ≥ 100 × 10⁹/L). 2
• Correct acidosis to pH ≥ 7.2 and restore body temperature toward normothermia. 2

Alternative: Fibrinogen Concentrate

• Fibrinogen concentrate is an alternative to cryoprecipitate, providing more predictable dosing (20 g/L concentration) with viral inactivation. 8, 7
• For every gram of fibrinogen concentrate, there is a 0.2–0.3 g/L increase in Clauss fibrinogen level. 7
• Cryoprecipitate contains additional hemostatic factors (von Willebrand factor, factor VIII, factor XIII, fibronectin) that may provide functional advantages beyond isolated fibrinogen replacement. 7, 2